| 证券代码 | SBBP.O |
| 证券名称 | Strongbridge Biopharma plc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2015-10-16 |
| 首发价格(元) | 10 USD |
| 首发数量(股) | 2500000 |
| 首发募资额(元) | 25,000,000.00 USD |
| 首发主承销商 | BofA Merrill Lynch,Stifel Nicolaus & Company, Incorporated |
| 货币单位 | USD |
| 公司名称 | Strongbridge Biopharma plc |
| 注册地址 | 爱尔兰 |
| 办公地址 | 900 Northbrook Drive, Suite 200, Trevose, Pennsylvania, USA |
| 成立日期 | 1996 |
| 董事会主席 | - |
| 公司属地 | Ireland 爱尔兰共和国 |
| 公司网址 | www.strongbridgebio.com |
| 电话 | +1 (610) 254-9200 |
| 传真 | - |
| 公司简介 | Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP. The primary focus of Strongbridge Biopharma is to build and advance a portfolio of vertical, therapeutically-aligned rare disease franchises. At the center of its rare neuromuscular disease franchise is commercialization of KEVEYIS (dichlorphenamide), the first and only U.S. Food and Drug Administration (FDA)-approved product to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. The Company’s rare endocrine disease franchise includes COR-003 (levoketoconazole), in clinical development for endogenous Cushing’s syndrome and COR-005 (veldoreotide), for acromegaly. Significant unmet needs remain in the diagnosis and treatment of these rare orphan diseases. The Company will continue to identify and evaluate the acquisition of products or product candidates that would be complementary to its existing rare neuromuscular and endocrine franchises or that would form the basis for new rare disease franchises. |